What were the main drivers of Bristol Myers Squibb's revenue in Q2 2023?

The company's revenue in the second quarter of 2023 was primarily driven by its key in-line products and the performance of its newly launched products, indicating continued market traction for its portfolio.

What is Bristol Myers Squibb's outlook for the remainder of the year?

While the full outlook isn't detailed in this excerpt, the company's strategic focus on pipeline progression and R&D suggests an emphasis on long-term growth. Investors should refer to the full MD&A section for specific forward-looking statements and guidance.

Are there any significant legal or risk factors mentioned that investors should be aware of?

The filing indicates that it includes discussions on Legal Proceedings (Item 1) and Risk Factors (Item 1A). Investors are advised to review these sections within the full 10-Q filing for a comprehensive understanding of potential challenges and legal matters.

How is Bristol Myers Squibb managing its financial condition?

The report includes Consolidated Balance Sheets and Consolidated Statements of Cash Flows, which, along with the Management's Discussion and Analysis, provide insights into the company's financial health, liquidity, and capital resources. The mention of strong cash flow generation is a positive indicator.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q2 FY2023

Summary

Bristol Myers Squibb (BMY) reported its financial results for the second quarter ending June 29, 2023. The company showcased solid revenue performance driven by its key in-line and new product portfolio, demonstrating continued growth momentum. While facing some headwinds, the overall financial health appears robust, supported by strategic advancements and a strong cash flow generation, positioning the company for future development and shareholder returns. Investors should note the company's focus on strategic pipeline progression and potential upcoming product launches, which are crucial for long-term value creation. The report details the company's operational performance, financial condition, and risk factors, offering a comprehensive view for stakeholders assessing BMY's market position and future prospects.

Financial Highlights

57 data points

Beta

Revenue

$11.23B

0.7% Gross Margin

Net Income

$2.07B

0.2% Net Margin

EPS (Diluted)

$0.99

Total Assets

$93.49B

Cash & Equivalents

$8.37B

Free Cash Flow

$1.63B

Financial Statements

Beta

Revenue	$11.23B
Cost of Revenue	$2.88B
Gross Profit	$8.35B
R&D Expenses	$2.26B
SG&A Expenses	$1.93B
Operating Expenses	$9.37B
Interest Expense	$282.00M
Net Income	$2.07B
EPS (Basic)	$0.99
EPS (Diluted)	$0.99
Shares Outstanding (Basic)	2.09B
Shares Outstanding (Diluted)	2.10B

Key Highlights

1Solid revenue growth driven by key established and new products.
2Continued focus on strategic pipeline advancement and R&D investments.
3Strong cash flow generation supporting operational needs and shareholder returns.
4Management's discussion provides insights into operational performance and future outlook.
5Disclosure of legal proceedings and risk factors provides transparency on potential challenges.
6The filing includes standard financial statements (Earnings, Balance Sheets, Cash Flows) and relevant notes for detailed analysis.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2023

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions